<SEC-DOCUMENT>0001193125-14-203933.txt : 20140519
<SEC-HEADER>0001193125-14-203933.hdr.sgml : 20140519
<ACCEPTANCE-DATETIME>20140519091733
ACCESSION NUMBER:		0001193125-14-203933
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20140519
DATE AS OF CHANGE:		20140519
EFFECTIVENESS DATE:		20140519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORASURE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001116463
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				364370966
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16537
		FILM NUMBER:		14853349

	BUSINESS ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
		BUSINESS PHONE:		5036416115

	MAIL ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d730110ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>(Amendment No.
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U> ) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by the Registrant <FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> &nbsp;&nbsp;Filed by a Party other than the
Registrant <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only&nbsp;(as permitted by Rule 14a-6(e)(2))</B> </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167;240.14a-12 </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>OraSure Technologies, Inc. </B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Registrant as
Specified In Its Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>&nbsp;&nbsp;</B></FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and
state how it was determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount Previously Paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing Party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date Filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g730110ima1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing May&nbsp;19, 2014, OraSure Technologies, Inc. sent the following communication to certain stockholders: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;19, 2014 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top">OraSure Technologies, Inc. (&#147;OraSure&#148; or the &#147;Company&#148;) </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>2014 Annual
Meeting of Stockholders &#150; Supplemental Information</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholder: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our upcoming 2014 Annual Meeting, the Company&#146;s stockholders will be asked to, among other things (i)&nbsp;elect three Class II Directors to serve
until the 2017 Annual Meeting; and (ii)&nbsp;approve, by an advisory (non-binding) vote, the compensation of the Company&#146;s named executive officers. The Company requests that you vote <B>FOR</B> the Director nominees and <B>FOR</B> the proposal
on executive compensation, as the Company&#146;s Board of Directors has unanimously recommended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proxy advisory firms of ISS Proxy Advisory Services
(&#147;ISS&#148;) and Glass Lewis&nbsp;&amp; Co. (&#147;Glass Lewis&#148;) have recently issued reports regarding the proposals to be considered at our Annual Meeting. The ISS report recommends a withhold vote for Mr.&nbsp;Roger Pringle, who serves
as Chairman of our Compensation Committee, and a vote against our executive compensation program. The Glass Lewis report recommends a withhold vote for all of our Director nominees, as well as a vote against our executive compensation program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the reasons explained below, we strongly disagree with the ISS and Glass Lewis reports and believe their recommendations are inappropriate and do not
accurately reflect the Company&#146;s performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ISS and Glass Lewis Overlook Significant Aspects of OraSure Performance </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ISS and Glass Lewis each follow a formulaic approach in determining their voting recommendation with respect to executive compensation proposals. These
approaches essentially compare a company&#146;s weighted average total shareholder return (&#147;TSR&#148;) (and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 East First Street,
Bethlehem, PA 18015-1360 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: 610.882.1820 &#149; Fax: 610.882.2275 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.orasure.com </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the case of Glass Lewis certain other financial measures) and CEO pay with data from a peer group of companies selected by each advisory firm. Particular emphasis is placed on TSR as a primary
measure of company performance. While these measures are certainly important and relevant in evaluating a company&#146;s executive compensation program, they are not, and should not, be the only factors considered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An executive&#146;s performance in any given year includes much more than the bottom line result or stock appreciation for that period. Executives often are
tasked with pursuing non-financial strategic objectives that are critical to a company&#146;s business, particularly over the long-term. An executive&#146;s performance is also often impacted by unexpected events or factors beyond the
executive&#146;s control. That is why our Board and Compensation Committee consider both financial and strategic accomplishments together with their knowledge of individual performance in establishing executive compensation levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significantly, neither of the ISS or Glass Lewis reports address the important strategic accomplishments that heavily influenced our compensation decisions
over the past several years. For example, ISS is particularly critical of the fact that Mr.&nbsp;Michels received an above target equity grant in 2013 based on 2012 performance, arguing that such an award should be questioned given OraSure&#146;s
mixed financial results. However, ISS fails to even acknowledge that during 2012 the Company successfully completed a seven-year, multimillion dollar development effort by obtaining FDA approval of our OraQuick<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test. This product is the first and only rapid infectious disease test <U>ever</U> approved by the FDA for use by consumers. This was a huge strategic accomplishment, especially for a
Company our size, and warranted significant recognition in the compensation awarded to Mr.&nbsp;Michels and his management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In criticizing our pay
practices, both ISS and Glass Lewis fail to grasp the significance of this accomplishment and instead rely solely on a &#147;one size fits all&#148; analysis in reaching their recommendations. We believe this is unreasonable. The Company strongly
believes that failing to reward our executives for receipt of FDA approval of this important product would be unfair and demotivating for these executives. While the use by ISS and Glass Lewis of their rigid analytical models might make it easier
and cost effective to evaluate thousands of public companies, this approach fails to grasp the real world in which an executives&#146; performance beyond short-term financial metrics must be recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ISS also criticizes the award of above-target incentive cash bonuses to our executives for performance during 2013, characterizing them as based on
&#147;subjective/qualitative assessments in a period of negative shareholder returns.&#148; This assessment mischaracterizes our Company performance and compensation decisions. As explained in detail in our 2014 Proxy Statement, performance during
2013 was strong, with record revenues, a substantial decrease in our net loss and a significant improvement in our cash position. In our Proxy Statement, we list the many specific factors contributing to this financial performance, not the least of
which were a 43% increase in net revenues from our molecular collection systems business, a 32% increase in sales of our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
HCV test, a $9.1 million net revenue contribution from our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test and the successful replacement of an important
substance abuse testing collaboration, which resulted in an $8.3 million payment and the establishment of a clear path for developing new fully-automated high-throughput oral fluid drug assays to be used with our Intercept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> collection device. These are not discretionary or qualitative factors as ISS suggests. Rather, these factors represent concrete achievements that directly contributed to our strong financial
performance for 2013 and thus support the executive compensation decisions made by our Board and Compensation Committee. Again, neither of the ISS or Glass Lewis reports mention any of these factors when analyzing our executive compensation program.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ISS and Glass Lewis Rely Too Heavily on TSR and Peer Group Data </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both ISS and Glass Lewis base their recommendations largely on a comparison of OraSure&#146;s weighted average TSR and CEO compensation with peer group company
data. While peer group comparisons are useful, they should not form the sole basis for evaluating the Company&#146;s pay practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For OraSure, TSR
represents the change in the market price for our common stock. A top priority for the Board and our management team is to increase our stock price and thus deliver value to our stockholders. Our stock price can, and often does, respond to improved
financial performance and the achievement of significant milestones. However, it also is often negatively impacted by a variety of other factors, many of which are unrelated to performance by the Company or its executive management team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in market conditions, industry developments, sales of our stock by investors for tax or other reasons and other factors can have a significant
negative influence on our stock price. A specific example occurred in late November 2013 when a large customer of our molecular collection systems business received a warning letter from the FDA requesting that it immediately discontinue marketing
certain of its services in the United States. Despite our disclosure that this customer represented less than 5% of our 2013 consolidated net revenues and that our guidance for the fourth quarter of 2013 would not be affected, our stock price
dropped from $6.99 to $5.83, or almost 17%, in a single day. More than 4.2&nbsp;million shares, or about 10 times our average daily trading volume, exchanged hands that same day. For reasons such as this, the use of TSR by ISS and Glass Lewis as the
primary proxy for measuring corporate performance is not appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, both ISS and Glass Lewis rely too heavily on a comparison between
OraSure and a group of its &#147;peers.&#148; While these companies may be similar in size and generally operate in an industry similar to OraSure, none of them represent a completely accurate comparison to our business, nor do they face the same
uncertainties and factors that typically affect our business. For example, none of these companies have been attempting to commercialize the first ever, FDA-approved over-the-counter HIV test, including addressing the need to build public awareness
and create a market for this important, but brand new product. Similarly, none of these companies are attempting to broadly market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the only FDA-approved rapid HCV test where there are significant funding challenges experienced by potential customers and there is a need to build public awareness around the importance of HCV
testing. Thus, peer group data should be used, at most, only as a general check on the reasonableness of compensation decisions and not as a rigid quantitative analysis of compensation versus performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Our Response to the 2013 Say on Pay (&#147;SOP&#148;) Vote Was Appropriate </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both ISS and Glass Lewis assert that our Compensation Committee&#146;s response to the failed SOP vote in 2013 was not robust enough. Each report apparently
reached this conclusion, at least in part, because we did not adopt performance-based vesting for equity awards and instead elected to continue our practice of making annual time-vested equity awards, comprised of 60% stock options and 40%
restricted shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contrary to the positions of ISS and Glass Lewis, we did not ignore the comments we received from stockholders regarding
performance-based equity. To the contrary, the Board and Compensation Committee highly values the input received from our stockholders regarding all issues discussed during our outreach efforts, including statements supportive of performance-based
equity awards. However, after careful consideration of this input, the Board and Compensation Committee decided to continue with time-vested equity awards that consist of 60% stock options for two primary reasons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First, stock option awards are already performance-based. As explained in our 2014 Proxy Statement, the exercise
price of our stock options is set at the average of the high and low sales price of our common stock on the date of grant. Thus, executives will receive absolutely no value for their stock options unless the price of our stock appreciates from the
value on the date of grant. Second, the Board and Compensation Committee were concerned that using performance metrics such as revenue growth or improved profitability, while appealing on the surface, may unintentionally create a disincentive for
management to make certain investment or strategic decisions that would adversely affect our ability to meet the financial metrics required for vesting even though the decisions are in the long-term best interests of the Company. For these reasons,
we decided not to adopt additional performance criteria at this time. However, the Board and Compensation Committee remain open to considering equity awards with performance vesting in the future as the Company&#146;s business grows and continues to
mature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In short, we strongly disagree with ISS and Glass Lewis that equity with performance vesting would necessarily be a better approach for OraSure.
In fact, although our stockholders did suggest we should consider performance equity, their overwhelming view was that they did not want to micromanage our business and that ultimately our Board and Compensation Committee should structure the
executive compensation programs in a manner believed to be in the best interests of the Company. Indeed, both ISS and Glass Lewis made similar comments when we discussed our programs with them several months ago. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After carefully considering the input from our stockholders, the Board and the Compensation Committee made the decision it believes is in fact in the best
interests of the Company by retaining much of the pre-existing compensation structure. We continue to believe this was the correct approach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Conclusion </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the reasons set forth above, and
in further detail in our 2014 Proxy Statement, we request that our stockholders reject the recommendations contained in the ISS and Glass reports and that they vote <B>FOR</B> our Director nominees and <B>FOR</B> the approval of the compensation of
the Company&#146;s named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure Technologies, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g730110ima1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g730110ima1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`50$W`P$1``(1`0,1`?_$`,D``0``!@,!`0``````
M```````#!@<("0H!`@0%"P$!``$%`0$!``````````````8!`@,%!P0("1``
M``8!`P,"`P,'"0<%`````0(#!`4&!P`1""$2"3$302(446$5<3)2(Q87"H&1
MH<%"DA@9&M'2)"665]?QPC,F*1$``0,#`P$%!`0*!@<&!P```1$"`P`$!2$2
M!C%!46$B$W&!%`>1H3(5L<'10E(CI-06"/#ADV87)V)RDJ)C5!B"PC,TA$9S
M@Z,D1&0E_]H`#`,!``(1`Q$`/P#:(YV^97C3X^<O06%\PT'.5HLU@H$7D5G(
M8VKE(EX).&EI^RUUNT<.;'D&JOBRA'E6<'.0K<Z0)'3$%!$3%+U7@WRBY%S_
M`!TN3Q$]E%!%)L(F?(UQ*-*@,B>$\PZD>RN5<R^;O'N$9)N+R=O?2SN:H,3(
MW-]BOE85]U65_P"J`X)_]G.6O_0V*?\`S/J:_P#3/S?_`)S$_P!I/^[U$O\`
MJ.X;_P`EE?[.#]XI_J@."?\`V<Y:_P#0V*?_`#/I_P!,_-_^<Q/]I/\`N]/^
MH[AO_)97^S@_>*X'^*!X(@4YAP[RU^0O<`?L-BK<XB.Q2%']\W8!SB.P;B&^
MKV?RR<XD*"]Q/]K/^[U5O\QO#7.#?@\J"?\`AP?O"T-_%`<$@`PEP[RT4[2B
M;]72,4&[BE#N,)!_?0`&`"@(]/4-4G_EEYO;L,C[W$%H[I9_W:L@_F)X>91%
M\'E=Q_X</[Q3_5`\$A#?]SO+7[P&C8J`Q?4/F*;,P"4=P$-AZ[AK%;?RU\VN
M7;67F)!\9)_W<U1O\Q7#W2>D+/*[O_AP?O%"_P`4%P/.`B3$'+$^QQ(8H4C%
M/<40WZF`<SAT';5Y_EGYP"1\9B2A3_Q)_P!WK$[^9#AC'%IL\JH_X<'[Q7/^
MI_X)?]GN6?\`T/BG_P`SZO;_`"R<Y?TO,3_:3_NU6_\`4EPO_D\K_9P?O%/]
M4!P2_P"SO+0?R4?%/_F?5X_EAYT?_P`W$_VD_P"[5</YD.&.*"SRJG_AP?O%
M5HXY_P`09P_Y-YVQ;Q^HN+.2T3;\M6A*IU^5M50QPRK4?(+,7\@5>;>1>59B
M2;L@1CC@)D6C@_<(?+MN(1;E7R.Y5Q#$R9G(W./DMHVDD1OE+M.X.A8/KJ2<
M7^='&N699F&L+:_CN7E`9&1!OO+9G'ZJSLD.!]Q#?I]O_J.N,5V`A"E=]*I3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI6F1_$*4`MIYJ8YD!0*J5+CA4V^XD$>TZ>1LIG+\P!Z!]0/3[]
M?7O\OU^ZUXU>Q@I_]S_W8Z^;_FGQZ'+YB.Y>`7-;^6L$W[GB!ZM4@WZ!N3;<
M?L#IZZ[K]\2?I5R_^#(/T#45##*2[A!NH5!F#A8B`.%B`5)$RABD!1P<X=C=
MJF8P"LL<!(V2[E3@)""`G9B1FKW(/'3\-4_@VV5"W6OJ2V$WU#M;Z)M,&1%]
M4YQ(MEKBH&`@$A'OO.6YS'#=?ZH"&!)8@^TX;^VNEL10->2\Y$Z&Q=<1O#D/
M4$'L[Q7LM.#P&<%[4[E%5.SAQ)-B;.D_C$C1-Q'MK7"RE0=($V).T.VKPEBH
M[U'N^447<#-MD3;"(G6!4I^@:BHYI+?<:FOV'S-+00JEOG#2"G1"H/LK:.X'
M"V_C!9V%-.NE?5Y0<82T7D[G7'4'!F$T;EZT1<!$F0%/ZA-Y)JOX"+;&3+WD
M3>Q+E`"CZE,H';U'7IQO+7NP$64W`>HP%5"*0O7PK%%P:V;?%B#<#4J9PXUQ
M>,\K7#'C1NT5-CA]&TV:="8WMN[%!PD,G<E5#AU3!.T&?MBAT``0W#IJ0V/)
M#>V$5\UWZJ6,.!71#J-?$5X)^"VXG>T`$AQ[/&I(L7'R5J;Y.(L$4FPEBL6$
M@[:G+LJP3EVB4E&Q\DF(!]--IQ3E!=TB&Q4OJ"%Z&`P!G.=DVAS'%S#VC4?2
M-*PG@]L/M``^-?##$">^WTJ7IOL!1WV^WTU5F>F.HW(GC5LG"+>-F\-Z$?AJ
M^GQD8N)#^07B1+`@0@L,O,U`$NX=IAKEC+N/V_*80Z_;KGGS9O\`XC@ER'%2
M8W?@J;<'XU'C.4VUU&W\]NH'L[J_0A1'<`$.@&ZC_3M^37PD.E?4ZKK7HU6E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E:SGF+H@6?DU3'`-C*G3PM76XJ;")`*G=;\J(#V@([C[FOHOY
M/Y$6V'N6GH9E_P!UM<LY5CS)?!X50/RUB<_=")#ID%L!`$05`AD"J"][!#=D
M450*"`*%$1%0!W*`=.NNM_?3"=>E1C[M?XU6$>)IK52'>0\:MU9Y"$0(^R#C
M\A0>VND)^T9FE/)B!%%[?C1^LW$4WJ!`6CSF,V>(]@%.:.Q<O9>3OL>0K&TN
M<V(N^RY#HU>QR:@'[0U!*$#V0\:DN7"<#[-5O/QM;\FN/A[?`I%?9PX^03&K
M7V,3:)_7Y$P\S%0*;:U3J=PR-BQNS:N(M=0#"=TP9IIG,94``T8=R%F'R;\/
M*Y,5?'>TDZ-?]DM]CD!:.QV[L(3=7>,=<6C;@`DP.#?QK[NVJXYKX])Y7P9P
M4Y&1[0KN8B&="P3D+9O[JJY:_:R0-7E'BY2',=5'\/4CU%#"`_\`$H"`"!=R
MQ?%<C^[KC*X.U(-E-N>$/9L!(_V@O;U/A4B?BW3?"7@7R,(/O:1^.K@+GQ,C
M+SY;92PRL44]1KC2J9XL('*<4'7X#6XMO&&7$R0MSD>W.(12[!-L9))7<=RE
M`VN')B[Y<P8QA_7^L6#VDD`^X:UIG<=]',F\</U>\N/LZI[^E678<XX15YN^
M;^8N8X?\5Q3CRTV?(1XUTU3%GDS)+^S/I&M54Z11$\JQ0E7+,7X`/8/5'<WN
M*@66Y7ESV6%OQ;$N)?*Q@=M[$:-Q\"!T\4K6V>`>R2:=/*7N=])5/Z=U6P0G
M'R\9JL-QO%B61:H'DI*Y94R'-IJI5Z`&4<N9"1,'8@LFZE7CY;V8R-:@L[<@
M8I$TQ`ANV:-YC!865MA;4K*V-'-'7=V?5U)T'4FM;-A'W<QE_0*:_35.Y/#\
M:F^<IQ#!X2/+WMVJ[U!+\0D&Z9NU%R_31.LW8N7"90.H1$ZA2&$0`1`-2.TY
M%/#`89%VN']=6OQCO2,)'4?UU<QP5Q9^#\P^/,L5J8GT&1FKP3"4X`":<+-D
M,&XD#YQ,H&WPV#UU".?7HNN(W"(I::VW%X?A+P*NT$?AK<:3W^7?;?;KMZ>F
MODQOV1[*ZTTJT'PJ/JZJTTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*5B-YU8M5NV786521]WV:!#L!$"G,
M.Y+!:E^T.T.@A[^_V["'W:ZGP7(_!6<D8*-+]?'05%,I;23R;G?9]E6IU[$2
M<:9TTG*O!6NNNBIA)0LR@Y2(H<J@>THSEV!DI2"DT2B)D7"1P`3@!3@)!'4N
MN>0.`1DA:5Z@!?K!'TBM3]WGJA-7%4OC3)1,TQRGQVL+M&>A3G4<T6VF8QTX
M@"_:$E#NUFX*0]D@WX;I+I@#<77Y_<"@@.H;R#D,^4#69+:2`@=&-K=.BHA!
M'754/YU2.PA,+`V+[*:@_P!-:N4HV$X$EVA,SXXK+C'5O20=5S*N+Y!`&43+
MQTHJDO--6Z9RF:,W;9Z@60;K)"JR<@7M$H*[F&)Y#.Y"[:R&YD#XXPC#M:H"
MDCS!"3JBJOTUL(\?;-@?`6GTWNW$*>J)I_55Q<!@VFP]2GZ*BU1+49BVFN,?
M#HIJI-X5\O),ILQ8_O,*K5-*>9"ND0I@!'?8NP:U,-[+;2&>W<1,X.!)U4.T
M(UTU!->MD;(XO0:/U8"`?UU,E@Q[&/WMOL#!,K.UW"G$HYI7L[EVD<B66.S$
M3>IB(.Y4ZH@/J.WV!K%'=3Q6[;5A_4L?O`1?-WJ=:H^&.0(\:5;#DCC3$SE&
MQUAF*=A1L,4$C6Q6R1;B5%Y.N&)%?8:M5#@8'!G[XR[N24<=QCG5()=SCJ08
MG,W&.NSD82#?'IH'#W@J!]&B5K76X:K&J&5;!=\*V#*,;!TG&%2#'F`J*IWU
MM"2,$)"RCIH`I+6Z776-]9+2:@=_L@=)54"*'[1*)A$97BLS8VMP^]R"R9>5
MX.X=->QK1H`#^!36ODLQ$2V`$,=J5UU[]:MXL?'>J0Q0AH%.0L;],!,[LH('
MAZVW,0=C-*W&""\@]:-#;D47>"EOT$I0]-3V'-9"\A$\SF,A_11JIV*0-#["
M?::\$V/!&_7<*G?CKAE>!SEBZ:!$H%C+25TH)2F$0+^&2"(?<'5749Y7D[PX
MI]HR1OP[AJ$"_2BBK[+&MCE$S6G>O>:SBH*.14,0RHB`&.!`!-$0`I3"'J`[
MCVATZZX:'1`D1S%Z%$#.G@J?CJ6137*;9;0L8--Q?H>X]>WKTKW>^!1*4ZI`
M,83`4IA(4QA+^=V@.PB)1]=O31KIYW[HV.9$W0[@B^/L2LIDC!VNV[ST0K44
MIC"8.H"4?B&W4/N$->KRD**JNW1WVC7<YA#;8=M]_L^'^S5M*\HK&W^4Y1`3
M"4-NT0W`?S0$-]Q#^?6%D4CPYPE<@/Z`T^K6L$D\;'!I<%)3W_EKNFL)P-L8
M#;&[=P[1#</4.FX;@.K+::*;<(Y/4+2AT1#W=!7I<T``@J"*](>@?D#7IJVN
M=*5TWV[NOH`ZKV54C2H/N&,&Z9BF#[MA#T`0^8-P#H.L,BE&ASFN/<W=^*L'
MJ2;2YH:4/:4KH"R@'*0XE*8P")2^IA*'J(=-M@$0W'5&RQ1N$,CW.F=T5J?@
M"52+XN0[W-:(AXK4;O-]O]`?[-9JST!0.NYP]?CL`!\`#<?OU4-<T$NUH62`
MJ3Y:Z%4/W&`Q@]?EV``';;K\.OKJT$G7:0/&JE\3M(^HZU%3,)N[?X#L&JU2
MN3B(;;??_5I2O,*QP,8O<'0IS;[!TZ_*'W[!J\,.S4^<]*L>'QVKI7'S+I[%
MKL14QO[0;[%';IN&_P`1#[!$.FK%_-((<.M4AD;+"UP*N36O2'H'Y`TK)74X
MB&VWW_U:4KSE6$1_/``[P('=VAW&W$.TOVF$0]/76)QF+M@86M_2T.GL4U2*
M:&50W[0)%1R&$1/OZ`(;=`]!#[M9`$`5VXU:TNW.!Z+I435:OKH<1#;;[_ZM
M*5YCK'VV*8`,(&[0V`=Q`VWY-61ATLN]I_4`H1X^VJ&6&.X;%*='!:C(B<P;
MG$!Z%]``-AV^8/Y]7;VN>YK.@-5+7-D<I_5KY?94;5:4TI32E4VMV-XNW2!)
M![L54C9%L!P$P'*5%913<H@4?4#@&MG99%]I$8]5)[*L?%'(P@KNKY*.(8(.
MU-ZRAY%`@=I`<1I$W)"CZ@#QN=-QU'[]5ERDLG0N%>?X1E>EOB&KQ[U&0B".
M8A\B)1!TT=+F.)2]`;]JHF$6Q"]``3".VO+\7*?M%:SQQAA6JCIH&2%-0X%4
M<$(5(RX;]RB8;;]_0![A$-_LUX+R4L;ZC%V@HGMKT.+7'R_17RYBSQ<"B1:3
M4.B54XIH$`"F5<*%]2HI@;<P@&HOR/EN(XIZ0RDP,\J[(VD;W)W!Q`^NLN+M
M+G+%XMHW!K#JYW3ZE/U5$C+''RP@5K[W>)!.)%2`F8``-PZ";<=P^S?6QP?(
M,?GK#XZV.PK_`.&\@2?0"05\#7IO,5<V+"^;;M\%_)7O=LVTBB*#INDX2/L)
MD'*8*(GV$#@55,=P,`&*`_E#6ZA?*!N4@'5.T>%:Q&G6I,LE!3M(`UE)-?\`
M"TA**$<V3(BB3;;H8H;@;;8-A^&O:RX8P[]I]3O6FQA^U4L_N,J!>I4U#F+Z
M%4V[#"`;?/L`CMKW-SN08WTV/(CJQ\4;F[4KW0>(X&#EF<NU113<,%O?;^V!
MO_D$ADQ$VY`_LF'^?6.^R]U=PF-2I[ZOB9'&$(^BM?K^(@RWF.GP7#_`F*,E
M6/%D3R=S8O3\@V&G/G<+8'$&S=U&)8QWXK&.&C\\21Q:EG#AH"A4WG85-0>T
M.O7ODU9V@9?9Z:TM)S91`EL@4%=Q):-I&XH`2Y$`TZFN.?-3*Y:2[L\%;74T
M/Q3D:6Z`=GF((/CH#5`/&]8+AP2\I/,C@Y9,]Y"R7QFQ)@:5RY]9E27DK&]K
MZM7AL9VI::9@91Z=B>/A+=().4F*:1'::*1A3%0HB.YY^9N:<7QG)K/'VMJZ
MX=Z4<=N`#N,I8C]&@[B$;]I`BH16EX/<V_&^37_'LOD7R3VY]1SYMR%H:I+$
MW(`/,X%.A`45G0Q'Y2N!^:YF#KV+^0U1M$K-T6^9,1:)M9N#_"J%C-<K6Z6B
MR_M!%Q1*I"Q"I_D5?B@5RF4RB'N)D,<.,Y'@/-\!O9?XVX)W1@;?3U,KVL:`
M"\$ZN"^"HIKJ\?-.*9#TY[2^A,1+@OG0;&DE3M3L^E*@<?\`RH\#>6N2)'#&
M!>0=>N61&J#YVA7PCK!77D_&Q9"*R,A4%[+$1#:R-F:)P54,U.H)6H&5V[`[
MARYWA7(N.6?QN6@].WWM:XJ#L+D0.3HBZH3TJF)YA@\U.^WL9"9HW(AT+D_1
MUU'M3V5JC7:@\K/(UR6\J-B5SWG>$Y`\0[(Z'C?QUQS9I.MA)PL%D*QU6/K\
M5#LY2.123CF\>@F#]I[*BKZ2!PZ74`"$'Z#E/%>(\:Q++G'6MU;7T36NN!J&
MDQ[M[G.`57*7+T:';>B5PAUQRGEV?R#<9.RWDL97GTI20Y[6O(1H8'(4&B]5
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MV)_)1K5./D'RB0B6/,`OR`8G>B4RA`-6;@W++>=EK+92BXDD+&M5JEP:7'3=
MT#6DD]``I(KS0\[XE/$9H[V+8`IT=VD`?F]I(&FNM=N+ODVX3<S[/-TCCIFN
M'O-T@6SB1?U)Y$S]4L*L(V.D52?C(BUQ<,\F(8HK$[U6I511`Y15*3<-6\HX
M)SGB.,AS.8Q%VW%32[!*TQ%@/>[]8H'N7L1:]V*Y;QC.W(LL1?0SW)"HW?V=
M?M,`T\*Q\^=+C/=K=Q_M_+ND<GLWX8=\9L2V-VAC?&%DE:Y5\@R4C8XM=%Y9
MG$/,P[L%&*:PMTS`4Y@1`-MO09O\G\M9P\DBX]<65K=37<P`?*`1&C">UKE!
M3L(KGGS<P.0FQ;\PRZN+6"TB*LC<1ZBNZJ'`!%_."Z)I5J'BE5H7#?BE3?)I
MR]YRYB>4[.N.W-5<T++UMM=OHM4GT\B2C!FK1VRLI9)^>LTBE5=A119B<$E5
M#J"0"FVW7/[;(<PYK<</XOAK=EY:%7.C#&[@&J2TD-#>OYQ!(Z:E*\'`HH..
M<6M^5YG)W,MK.?+&YSB02H\P4J!J=%`_!G7P+Y#.(')K&EORWA?,]=M6/\<(
M.5\BS;Q-_5U:&FWCG,M[MJB+2SAY>*;.8YDJJBN9`6ZI$S]IQ[1#7*<OPSEN
M#S%KA<GCYX[J\9NC*L<WV':\E3W`'M)TKIUGS#BMY93Y!E_"RVMI`QY<'A"=
M%T:?+X^[K4A\;O*9P/Y@9#?8FX_Y\KUTR(S1?/$:RK&V&O/YN+C0.H^F*P>?
MB8UM8H]HBBHH95FHJ)"$[]NW8=9\[Q'DG&H67.1M7NM7%GF86N:W>B;M0B+Y
MAJ>HK):<IPN5+K.SNH_B"'[021N:PE7-T5"`H)0IU`UK`]XIO)3ACC%.\[O\
M:')B:9*V'F!*0&+HN\3MTO<E'PK)[;6[XD##BI99"O4:&(HS(X?B#>.34,1,
MQ@.02EZYS[Y992YDQT'&;-[W,QGK3N\C02[:X)JI*'N1:Y'PKYCX:RM[JZSU
MT(Q/?B*)I#BX;06DNT0!1V$E.RMA3-'D:X8<;[56Z3G'.E9QO9KE2'&2JTRG
MFD[]#*49NG(*#8$;"QB7=<31<#&*D004=D=.%.PB21C*$`>/X'A/+.16TMUC
MK&4PPR%CB71Z.!`(T>>_^ATKK>0Y9QO&WD5A->1&YF9O:!NU;M+NUH10*ZX[
M\CG#;*O'6T\KZCFF"-@2C2<I"7&^3K.7K+>MS,49D1>)E(F>8,)Q&3<GD6Q6
MK<&QEGAG*0(E4%0H#CN.'<JMLY!QZ2QF^\;@*T`L0#4`GS*BA%[.U!5G\68+
M[G&<$P^"+]O^DNNB>[O_`!U2.@>2'B%S3Q?GV/XN9QC;?;*3BB\S4C%HLK#5
M+9%L!K4@5C96$78&$)+KL4G2R0E<MRC[*AT^\2"8N^R'!^08#EM@,ZQK;&6Z
M9"0#N1XE`>#HG0$=JJ/%-7=\IM,MQ^\GQTFMO&]Q!T)`:3Y4)^LCQK&]X.^7
M%/PWXI)K/_+?.<LVK,!G7(D;)Y$RI:+!;)0J?M5PL-`LEWJDO-R"KA5P;Z9F
MV3.8#F/L78.[4T^9?";D?,@\4XO;.FF,0<XL+0P$ZJ=Q!&A'9U'CK'OE[R:"
M7C3\MDY1'"YYVAQ\R-"'O&I&B'VUF*XO^0?B9S+@[)/\<,K1V0BTP&RUPAP8
MR==L-6:/CN"L)&<A+,TB7[.)?%:*&1=@0S<Y2#\X"&VN;\FXARGB=ZRPRMA-
MZTC@UI86.#B2`@.X*4*H-2`4!-3W`<EP?(K66\L[ED<,"[_44$`=2C=VFE4`
M#S9>,-2>R!6AY6TE-YC:-EY6Q/EF%C1A'+2"35/*_LQ,JPQ&%M7;JHBD1...
MY.X5$"H@IU$-S=_+/G%E#+-/CY0(0W>%9N&[H"-VAUU7[/:E:"'YE\+E>&"]
M8'&38%:_4]X\O0]AJDV"WV"YGRI9SOE2YMY'OV2+#@ZO3TCPVDVUK;8WQM39
MF`QL]B<A1+J14&J(/Y"/59NC)$!-P0TNJ)@#J&J9ZTY!#Q*QN)L7,,?))Z+7
MM,6XN#B'%PW-**#VEQ[`35,/>VISMVT7<+VM+I$\P&TZA"1XCJ!5P5)\O7CK
MON;$N/-4Y+U&5RD]GE*K$QA(VT-H&=M:3CZ,:O"7-_!M:A)3BCO]4DBF]'WS
M;>T)]PUY[CY7\TQ,$]S+CKD00QB20DM.T%NX:;R5VZIV=J%:V4/.>*7$T=L+
MR)D\KMK&N53JA*@$`!VBDC7HM?3Y">6/@1Q7RBUPQG;/D#2<D'*P4EJY^%S\
MZK4T9-!N[8.+D\K\5)L*PDZ8NTW)/JE2&^F-[PE!/YM8L9P3EN6PPSME8RNL
M"2%5BZ+T`=J-.HKSY7GW%L-EGX>]N4NV@=&NVDE-%0:Z]M7\P-DB;5"Q4_!.
MT)*%GXMA-0TLQ70>1TI%2C<KR.?L7C=11%RV>,U"+$,4>J9RC\=1%HN&ROAN
M89(9(W$$/3J"AZ$]W:E2Z.>">!EQ;2-DC>`1M[B%[4K6M_B-,BY(QVQX&CCZ
M^W>DEL?(MY'SJ5*M]BJA[%&)-($@Q4Q^!OV:$@R!5Z*A".$UR"??<NVNV_)_
M#6.4XWGV2M:^XB@;(PH"BNE+D/52C=.FE<;^9V2R&+SN,$4@#)Y-H"E0?*/-
MV(.Q-=:RU9I\H?!;C5?[OB?-.?*[1\CX]JT;;K14I2/LAI-*)DTF81:<4L6&
M,RL,M*`\1^G9,EEWBP&,8$^TAQ"!83@7)N01LGPUH^6&7<00@'E/:2=.U#TT
M3J0#,LGSO"X*0V64>X7,18UR(0=P50I!*=JIK4U/O(WPUB^,T1S!D\V5V.X\
M3^Z$'?GJ,DW_`!:6*]=QJM;8UU1F%H6M*$@P714C_H_JB&04$2]I#"'@M.)<
MHO,P_!1V$XR$84@[414W*''0G0&MKD.58#&X]F3N;F,6L@"$:G5-$[]?PU,W
M%?G5Q<YKUV:L_&7*<3DYA672#*SLF;63A)^N.7J2RL<6:KED91$TR0E"MU`;
M+"B*"PIG`IQ[1VQ<BXYF^*WD=GF[=\+Y/SM"T>TJOT`UZ\?G<1EX/7Q<[)PB
MHWK[-4J[8#@*?N?#M$VVX?`-Q#??M_IVUI4"HH3OK:*[;NVG<GV>U>[N7WUV
MW`?B'\^K5'3MJZN=5I7`B`>H@'Y1U3<WO%*A#L)P,!@$`#80`=_4?NUBG<!&
M%_2%6;'&7>OEVI5N^:8^6)(P-@8MW#QFR3=M'**(*G]@ZQBF(X!-,H["`DV[
MMM]OCK\]_P"<3%<PQ?(L9SO!LNKC'V(5\4+))2=P+/L1AWZ2]*ZU\N+K&RVU
MQCKES(Y7D$.<0WH=0I2O-C65FIV?1<+M'+=BQ;F^I=*I*D*=0P=J+9,IB`00
M-L(F,'4-M;[^6[(\KY_EHN29"*[LK&U'FCFCDAW)W-D:TGZ*KS2SQ]I;>G:R
M1O<XZ!KFN]IT)JY-,H@4O=MW]H=PAOMW;==ONU]XN+226_9KE!ZZ=*B:M4'H
M:I35:5QN`>H@'\NJ!S24!"TK5F_B,3%_?!XL![@V#DF^,([AL!0L^)]Q$?0`
M#?UU]!?)ICW<:Y"&M<2+9I*`E!Y]3X>-<+^9SFMY=A=Q`_6=I\:H#93`;SB>
M6?M!-7L\?&7A`ANTY"*IX4Q&<1[1W+[A0VW`0W$O3T'6SMS;P?+WC%U++*R8
M7S$:T.(<T7A+CH$+AV#KW5H;B*"YYUR&!UO'+,;=Y#W$#:/1Z*2$!/7LJ>/#
MAPZXNY>\05YN>4X>&HUAR@AGJEY5Y$L$(9ADZ$QE&/T8J39Q]UG(J;"%A&E2
MB/HU$BMU&YFPG[D5#"._C^8W->5#YJVQP]Q+-;P>D6V[P?.Y/(K"FK7%?,@Z
M%0@-;7@7&,(>`2,SMO#%;R3/+I6EIVM:00C@3JX@@[=3J#U2K!,%7/CI)>5S
MQ85CAW4[Q"8!Q6VG,3T_+]XB8Z"F.2/X6^R<G9\@(_1QT6YL#)O(R:\4:1=(
MIK.SHB`)I$(4@3+.6N3N?E#R"?E3V/RD^08\`.!=$4:"T:JT#:N@`U)U53$\
M%+8Y'GMM+QV.2"RLRT'<"WU`7%P=T\Q(<.TD(`4(VC(KY;<,Y*X%<N<7>8#C
M'&N%X0LI&5+EA4(0YQ9S<?(NVD:,O,H"0&1H7(D$V3C'RG0S>=:L')3`J83A
M"?EK(SFN$N/EKE)`VZA@+[=\GE)+&@[6%W4MU(3LT[*E?,8G\2RUO\PL8PR0
M7%QLG9&-R;B5WAJITUW)K[:C>1[+%/SWS8\!V9<<28R]%R=?6%PKCM-45%Q9
MR]\Q(]!I(*)"4HOXU<YD'*1B_JW*!P-N)>F/A.-N,9P?E-A=S/BN+<[7#5)$
M:Y`=.T#M[#6?FMW][<MP5]CGAMO)$7(-$!)70=$*CVA*L8H)05XU?Q,9R=HF
M+E-N0IP'O`I3Y5RVN8_7O[S^\IW=P]P]`#T`-3/(231\VXD)+F;TS9L`+FN`
M8L(!+21KH4T[*@%C'>CBO("\&4?'@EJ]1Z[=3X#JOOJHV9<'XHQ?_#=5#*V/
M:'6*9DW,$-@USD_(\/'I-+3>E'N;T'OM6RP)@,I(PZ+AND)$!.*+=%(I$B%(
M4`TX[=7%_P#/O(\>GO9G6MK#*]I=NVM_5`@C30G5NFJ$]AJ6<@PMA8?+V/*0
MV$'K%C5(+225=TU0]GO'>M1_'#!V_(GE%X0YKH'#?,_'["U3XADQ?<KA,8G&
MK4VUVV*P_:4D[PI;:^@2N3$3>G,HR4;N7)BOG*Y$Q4*.Q=L7S.O),9\JY./7
M?(/O&XNLD^9D8?ZGHQEY<UCNNPL&A&@:1[:UGRT?BW9JVD;CY+*X,+5DV/:'
M.V^9RD#[75>T=];"?F-V)XNN:8#OW'P^]'8=M@VFH3;M$O0=_77$?E2UH^8F
M*$6KF2(HU+O([7Q]M==^8NR+AN2C=,Z5KXPA=T;YFA`O?6J=R7E"1/B4\&JK
M^(D+/7T,SY!FI6G1S+\27MA8F_S*RE?;Q8G32D7LXQ5=-$D##VK&<F`P#N.O
MHG!FSN><<RD?<.LIO0C#)V+OCU&XMV^92B%-47LK@66^*L^%<?9*SUK?UR3$
M>CO-HH/8.OM]M<6&`R$VIGFZS1_AJS#Q/Q'FO#V,UZ-4<AXX5QK#1K=QFZMM
MW4(Q0:D0A%WR3>0=#VL2F(@V<@4WR;!KT1MM;;E?%I(,HS,7D-J\.)=O.[T9
M`5#BYP731Y7IVU;D9I'\=S/I8^.W$MXPM82&JW>'(`[:H!'8$TK+KP-\9#2_
M-?$9SOQ_;JEBM##O'BI*Y)HL?24#S>7IJ>C+6F^EI:TPK^+1-*@RLP$,LZ;.
ME5$4MCF,`!MQ_EWS%R8QN;XA>,+Y;G)[VG0B)@+1L;VM`0Z#0.7I77.-<#QU
MUE<5RV,-B;;XY'LU4O#7:HNH)(U1"T-15UU^+=3*B]X#>6.\2%5KK^XPOD'Q
MO6H6XOHA@[L\)6Y6U7I=_!Q,\JB>4BXN054,==!%4B:JAS&.`B.NX7%UEX.7
MX[&374C(W<=<4C)<"-L*%P:H\NH4CRZ]%-<4?:XNXXO<9.RM6N>W.``O\K@'
M>J4"H4<$7W=U9C,U4^K7_P`JOA*J=ZK4+:ZM+\'ZLI,5VRQ;&>@Y=1E1+U(,
M5I6)DV[MC(&0?LD54P7(?M42*8NPAOKD^(O[K%\"S]U97<[7C)[6[-P7=)&%
MW-^R2JDJ.\U/<S9QWO+,<R:S8R,V:EP11^J=TU4Z#Z/"L0P&/&>&;FO$1O<S
MB_\`-%IL6,:T[DF*D2WIZJI&"B"(E(9F7\*;&[/S0]@@AL)0$.FY:Q=_BK"P
MW<N^'$OEW(X."")P:B*A+B?;4<@AQCN"^F7/]/X]@#BJ$_K=`3H>G37H*R;4
M^HUC&/F7>5G'D!"TROS?BK=JR\-6(UG#13]V]X[H33YVY8,$4&AY-Y(1;9=P
MOV^^L=$IE#&]=16ZNW97Y>V&7NR^3(MY$?.Y=Q!NR@4Z^[LZ>%;6VLGXWDMQ
MB[9P-A)BMY:"J+:@DN'9YM5/;6,],#/?!GQ<BENY9E)^3>Q(R3`P=S=Z@A2T
M3I$<H&`2JE1.(F#IT'7OR,D\'S&S64]=\,L6-CE!:"2J@`%`4[T-:G)?!MX;
MBX6;BXWSHALUW-=M4A.J'11VZ5EYQ%5:]B[S%^7>CX[@8NF4MEPAL3AA5ZM'
MMH*!9.4L9XO>IK,HJ,2;,6HD?S+M?Y$R[K+J&'J(ZT67EN,IPOBN=R-]))?7
M658QY>2XC;(Y'%Q74`*JKV5N</;V6#SW)<;91ND;;X]SVQZH20W1/!1UK&[Q
MIHV))F@_P^*0T_'4K8KCRMSM%Y33_!:R_F;>R8Y3@1BVEZ;`W5>RL6@R4$6R
M+\AVY$@W3*`!K>Y?)Y2=O+7R7=V(H8XS$2V1H<GJ*6$@`]BN;W@DZ::FRQ>/
MD.'#;2V?+-=-W@/8YP5PT<`XD)X]$2LID+LR\[?D_2C=V247P,FDHELR,+5L
MT$F(L0"W]E)`4TTP0,@F"8AL"0%`"[!J&W4$T_RPX[,Z\>9),G_X:DD$RO&X
M=Y7S+J234M=]UV?-,Q;AKVRLMI_*`Y`!&>@'0?HIITK`A@VOWG*G$SB51<+\
M0LS6G(&,.7Z^3KMR2HF*UYZO2E6>RU>3;U$M[JL4O,O9>EOVZ#IPDY*#)H@'
M<41,/3LW(;DX;)Y2>^S.[$&QA9)`7^</:TE1&2JD%-&[N\HE<DP44&4^#@LK
M![\FV\>63R`M8&NVHTO<`U&EJZN(5W8>N7#D'C;`N!/+)R@JGD8QLI/<5O(C
M'5UWCC-RBK]HTQ_--)BO22:<7;8]HC-U(&<^P",E56+EL\;-%T#*"HQ4.F'-
M./S97(_+2SS'R\OGR7N,<XSVRDDDM<PK&"=P1P>W<$"`Z$:=3O;;%V/.[BWY
M_8PB&\C:(KAJ%C=0X)(.BD(HU/3H==O##>/:/B/&M#QECEB$=0J'4X2JTMB,
MP]L!T*K",R-(8OXY(N';Z63.R`ARKJJJ**=VXF'?7S#<WF9RM_<W&7:`]\A)
M\7'0]$3ITT1*[[;PXV!EO!B&D6[0@*.#=O7J5!5>JE>M:WO\3")3,/'@=-01
M*;DI*`!DS["4Q6M4-L!RCN4W<'Y?AKNWR+<<=C<\P`N:VT:2$)T)DZ^`6N._
M."QEFSF&+BA^(.G3]#IW]*H1R2HE,OWG#YW1]XJ==MK.$\:.1;3#-K)#L9I"
M(LK#"-6;M)V-2DD'"3*8;-WBJ:;A,"K)E6/VF#N'6[Q64N<=P+C\N.N);>9^
M2]-VPN&]CKK52W[0#4!&JC0@]*B>0Q=GFN:9J')J?1LG/9W;FP$@_P"L#J.W
MNK&G)I!)>)KQ$5]]W/H6P<^<G-;!"JJ@HTFVY;P6.%%X@KWIK_\``2CE/<P#
ML1PK^D.IDV&_L?F%R23$73I,A:8V.2+<#YCN!+2HT`W+JBDCM2O`ZQQ64XEQ
MZ*_;*ZWGOY&2@-<7;0U$(&J`AI'8%)K:[X?>-(>(W-OEQRAK>2*L&,N33)DP
MK&%ZS47%48X]!C)1DB15-9N_7A'@-B-'?L`BS;@071P#Y1V#YTY/S#+<PQ$6
M-S0?)<6C`T2G5[@&EJN<?,XDD$E3TUKM_#>'8GC][+D,.\>B]3Z:GRC<J!I*
MH"$&B)67T#(BT$H*E$H("43`<@B`>WU$1`1*`[#O_+KFX:TVGI!P7TT5?#K7
M0B]P?ZI:055$^K\54WN.3H>G2A(N2*0%3LDI`#&43(0S=9PX;%`PF,!P."C<
M1'8HAL.MW9XU]WYHOMUB>=C=Q[*EEOG&O/7"+5FT^J<.%`211;K^XH<YAV`H
M`4@^O\VK[G!WHZM.E>?XEO=4T2>4:U`HE).O6C&2.!>V&(L1W(I]Y@*0JR#<
M5.PXF$"]HB!@-ZAKR'%.8W>%VIU[/=W^WIXT^)';4XL99-PT8NG27X8>2.";
M-H[$B+A54Q#*D2[>X2BJHD03%+OOMKQNMP25[*S,?O"U]7?W"?,`E(H!0+W@
M'S=X;B`D$=P$OH(#MK#+:B2,QM)"U?IVUU1;_3D]H@I^V'YH%(1,"[CU`0+T
M$1$?LU6"WAA:CB21WF@`'LKQO)+V&[A9%([LS(>UPS0,D+LVP;[$3.<H`8Q`
M[BE,("<O4N_37LC:V1VT=]*DB/R95[`0X5U^UDY!`JXGAU'/X?)B+<P%7(B@
MY!,JQTS=!`!WW]-738RXC>"UJ-\/Q_UUBDD:P@=IJ4W&=()FL9L_CG+)<AS)
M';.062=)G((E-[R)D_<2*!@V[A^7[]>T8NX>SS#R&L?Q(KZ,)F2`G):/BF9"
M@M(.0:I)BH`B=0Q#J@.Q^T1`I4Q]`'5UU@'V$'Q2)3XD'V5A'\]?%#D'GRJ\
M6\O<=L</,N6/B]EYW?Y_',.IW6>PP;UU6WJ)(.,``5EVY)&L$3=(H"9T1!8%
M$DU.T0UU/Y,\DX[B'Y:SS-_);1Y"T],$%VU>A:?9H>[[5<F^:&'Y'D9<=F<7
M813?#S(IVD]B+KT/7VU9?Q0P5S&Y)\M/(%Y`LN<7KWQSA\R<1<G8GH>*[@20
M&Y3]VL=(JM7CV$!7W;*/F7:(MZ`8ZZZS%F!EGJ12>Z'<*<NY#G>*8;#\>XWA
M;WXOX&Z;-*YQ38D_J'J@"CH!47L,%R;(YG,Y3-6HM9+FW="P-1'![$T15]I-
M55XQ</>4;;^'KS1Q;EL572B\A9UAF92(QI92-X"S2S>2NS.S-X0J:CDY2)VV
M)25;(`<Y`5!7VS"3NWUJ[GEG';OYWVW+KA[#BG.8'/[O(6*O^B0TGNZUM&\=
MREG\JOX>8"+YDNY._P#6[O\`O%.\U8QQ!X^<Z);EGXD+5D7@_E+#.-^*]3<8
MGL=F7B635H*+"0N<W+7VVQ!6S5W0(:5F[.)&R"I5?JS%45*J8!WUN.:<HXM/
MA,['C9V/EO+\/:%'38QGE[V@`'W]U:+#8GDMOG+#U87B"(M7KJ-Y<23[R/=W
MU\;*^&?(GQ*G_)GQBB.(&5>3N.^=-B?&H.7H%Q/VBM5^&?6&?DH&4<I%2FF+
M-ZQ9VDS55DY/%`P?L4E@760W+K=X9_!N536'(X[V"PO<=`P2,>X-=(]D6UR>
M)<"2BJ%Z%"-)FSSS#,NL!9PR&WO)WN5"B.D)7MZCO(]_0U1R_P`(.;/'C#_A
M7GJQQZMO(3('$:<O%BRC0Z`[3D9*NS%IR?`9+K-/EYLA5(^,A19$/'NGX%73
M:N"'[1%,.X=%BN4<(SG\3VF2O76CIC%Z.U?UNUI#G@)J>G9T`\:WN0XQF\<[
M#W]O&YTD5D]D@_TG2;@T]RZ_37V\-<2N9Y>+GG+C,@<8[]3<G\IK%6K'C6AL
MT&DX2X2+V\WJ5EXRBS;+Z5C9F4::93*FZ*FW(X2#W`*4!`-8\SR_BESS+CSK
M?(&XLL?:@O+]R,#8T'4=KD!`[4K!C^-<HCP&7A;$\3WK1M"'4^HUQ`]P/N6K
MVL@\*\_Y?_A]L7\4HJC3L#R%J6+\83"V+9Y)M#V!S-T:]%L<I3%ROUB,VTI)
MQ*:J:/<J4AUNT.X-]]1WCO-,;9?.R]Y3=/`Q%TQ\9<50!S$!]B@`]P/A4OS.
M!REQ\I[+&6["<BU[=$U7<Y4\=5JDGC<J_D9RSS:X]9#RWAG/'%?C1QBXK0.%
M)R@WZV6-A2LF7.!H;NF1LW$45XNRCI99](.R/SN?HUP8%9I$^K.;;5W,1P7'
M<=N\?A)H9LA=W3Y$:!Y1(_<0H_1!/4J3[:U7$8^8WF?M[;,LD99P1B-2J'8$
M'7O1-.E9G?*ECJ]99\>/*O&^-:K,7>_6S%KZ-JU1KK7ZV;GI(9.*62CHUIW$
M]URJFB80`1`-@ZZYQ\JLC;<=YQC\G?.#(K;<"XE!MVO_`!D"NE?,7&?>G&9\
M9:A7.+2@UU#FG\`K7GS7P4Y;RWB:\8"U2P9;I_-'#C),OD6^X#?L56]_<1+O
M(,U,$39UDHJ.GL@U.@Q$R:8F53:NSJD*?;M'JV)Y1B)^5YOU+B*"VR.P-E)1
MH1P4$]!N;NZ]>E<RS/'\O+B<;+8PF:]L0[R%$=Y=%7L!1/&I\JW%_P`CW.'%
MGE?N^8*IEC$$5R3J<.RXR\=,R7J:52K<U7+7&W5VVB*W+/20]8;/64,6-.[^
MB8_4K.P*)1(F!M+C+<%XAR3$6?%Y&&9A;\3=-;H\F,QEY3<FKMQ0Z`:DU2RQ
M?,N2\<R%WR'%Q"_8"8`X@J=RH"X@D`+J0I(J4>!&(O(WD3E-X]HF^X*SKQ8P
M/P8P^RQ_D]:Z6N>K]$RJ\K!;1^".FE505C(>R2LT]G&S(?U$@!$6QSG<"F*9
MC4YI)PFVP%Y/8WD5QD[R_DD`:02W>-J@KJUQ5ZE/M:#OMX7/S6ZY)';W\!CM
M[>QC:[0AJ-3JNBIY0!IM`'5:MFL'`WFHXX"^3S'[3C!E]S>,N\Y\?9%QA5$Z
MV'XS>:1$3UP?O[+`H?5"FO%H-W20F.8Y1#W2].NI79_,#`V/,+7+>M'Z4.$F
MM7$$:.?L0'W@UI7\.S<G'9<>8W>K/E(Y.G8T2`GZQ64VY\;>0K_R;>)'*C+#
M-_>XYPGQ)KM)RU=&L.52`QY9V5+O$8YA+*X%P1PTD$'TF@0R943B45"ZYY;<
MDQ%E\O<SA))FMENK\2QH=2`^,@>PAI!\%72IG<87+S\RM"UCMEI9[3[XBP_A
M^NL<=,\:?,N\^+/G-AU?!EPJ>5)7G!&9RH-&N#-"$G,@TNOPK:*?.ZD5T\2:
MN'JS-XNNS(94HN#M_9V[U"E&?3<UX4[YDVV:O,I(;*YQ[H7O5RL?MC#1WH[:
M044@H3I40;P_-CA#,$&.]:WOQ,!_HK)N0?\`:%7&<0,'\S>0W-W(W,C,G%O(
M7&VL43@I-<=8&MWTHH6#(V0RXQ3HL:O7HY=!D_DB.6[9TY6,"1VZ`+-T_=,K
MW%+IN0<CP6,XY:<8PUR;B.#+?$EYZEOK&0$]W<.\^)KW8_"9F7+Y'D$L1#+G
M'NMP@[1#Z8]JD`GNUJV6,\<_,^9\*V/L?ML"9$B<]8;YMSV;E\*ST8UB;O9Z
M4Z@V,0+F#B72SE&55%9P54A$CF7,@DL8B9C%`H^O^.N-7/-KR^FE:,?D<:V)
M[NP/:XKN[1Y0$*(>BUAAX/FK3A>.8&.^\;"[=(&A51Y!"#MUJ^W@]C?F->N8
M7D-\D>6>,$AQY/D/CT_IF,L3YIE&D8E9[Y#U&L"U:2P2H19XNCG-CY,[^1D$
MFC,X2!BD[DR*"74\ORO&?X<X_P`0Q$LMVVRO1(_TD]4M<YP1A"`.\Z-[=/;6
MQXU:9RVR.?Y;DQ%#+=6;FL,H\B^5=P0J$:B(G2L1OCMSCQ-XASU.Y?\`(W@=
MR$9SS2^6J-_Q2TU\[GN-=1L\Q-2325E\?8\5C8Z%8)U*.D'#%I]%+SARMTS_
M`$7NJ"&I]S'"<WY9:W>/Q^1M!B/A`EF#MNMJ#RD[0Y21UWD'WK4&XIE>*6$]
MK=1X^ZBS!N__`#3O_*JOVD4M.AZ;`0>O1*S9XQXWYIM_F+YP9W)CZT17'3._
M#LM+QAG-6-,?'MND[AC;$D3%$@9)JLZ>N!3]A90QC(%#L;*&WZ:Y+D,YBK'B
MF`Q,;B<CC+AKYV$K(W9*XD.7\X`(5/7MKJV*X]E+OF67Y)D-ICN;=\4;Q]AP
M+0`6']$C4>%8M\`<</+%5:=QR\>=,P3GO"$-AOE=8<IY(Y*U>YOJCC6WX_E5
MXY*0BUY^NKQ4/8Z^"#)95%HC(/5GBJJ!!0*8J@!-N8\A^5=W=WW-<E=.DO;Q
ML0;#&TD^5J/>Y`H.K6H4T':ND/XI;\WQ[H^,Q6+9L1#)*]SGIHYSAM"D]`A<
MO>>RKIO*/&>4G.4IR?XA7'ATYY,8BR#=*K.\.LO4&HP,?%X79QEA^M)(V*R-
MVYCJSCB!,$/)&DG#`B)NXQCJMA."GGX%D/EGA\;;<HX]E7V%]\,X7D(+VF1S
MHR'``]1O&\:=.P)5W+F_,+D,TV$R./8W$-D2)XVZ-#@A:05!+="`I"$&LAE?
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M[$>0?'ED+&E.R*V@7"M7G[[)XQK<)'5./>E_6K33V3CE4BI`GL!@ZFUG@Y)C
M(>%X3$F1@N["^$KFJ%#3.)#]#0M::[XUF&\LRUZYCO2GMGAI15)A<T?6X#WU
MC]?^/?F,MXB>"Y(S`%T5S=Q5Y77G+MIP7*LC1V1)"HRUJ?/D7$1``F]6D7*0
MH-#G23*HJ=N)SI$5V`HRF/FV$R'-<Q+-=?"VF7LF1"<*-B2-<[4=I#!]-::?
M$<CQ?%,==V+'_>$%U(0`-=6D*G7H'*O8E7Y<(`\E+>^>2/G]>,`93J+^]X_]
M_C9Q`RK<[3.&D+S'';2RS"&J@N6"4#'N/H$6AEVS&/674<&`"*%)W:BO-&_+
M.2]Q7#</D7OAT;<W*/:T>5"\=40E2`53MK?<4/(K:UO<_P"D[X]ZN#3VN+@H
M[.@)[-.ZLF7&GDKS@R+P0S1G?-G%-;%W*BH0^;'F->/?T,TG^W;NF4M:=Q@W
M_#7DHZG]KS92!'^TFX3,<2`!.T1`=0/.<;XG9\SM>.XN^;)QN2>&"6[701/>
M&2RD@`HQGGU!-3S!9?D5YQ6\R.181EHHY7QM(17-9N8`.TE^G=IIUJ6>>^3D
M:9F"#B5#&,*^/HEW[?N`0I_=GK,01]0'\Y`O]W4BX)CFW5H^X+5D:\IX:`:C
MI]/?6US.1-N1$UR`^RK0F7*!Q$1"S&,=%A7*_60ETW"A79T`W+]&04A,*;1<
M##[@AL&^W74]=AC)]M@/NK0?>DB_;_!5?L49.I]'AV6;\N/P8Q+D7:F-*@U*
M)[-D!\Q$Z,A)D;.C+ND:G%'V*#Q4"I+G/W%$=B@//\EB[G.WAML(QT;(R1(3
MJT(2#JY=204#>@U*:+L<?D('L<;MRN70*A^K^GUU6['O)K\6B<B\I,FN$HJA
MU(KBJ4*JM'AWC28LG<5XX"-46$"/Y5L@!&Y%$TB>T)SB81*`B&FN^.;;R/'V
MP/J"/=*=3T*;O!>@`1==-*VEI?,:'N)\A=I]'1?"KCJ=G4S5CQOAK&=H6TYZ
M))39F@+J+_AS!>#D+*11(Y]Q,3]8U;$'T%8QO4-M:";&S.CNI6+Z4.B]VJ)X
M^^O;'>,D>&`A37TIC-X2<SR!Q_#@E^VV'*[&6MA'$6**DLT>59"<#M,!>S]5
M*(K,S`;T]TAOB&O+/@9VV-A>$.,=Q(CRO7S$%.Y1W?CJV:^B!,49'JU;?>^3
M*"%2H'*G&AA?UI17]D,I57ZM9$[.0=JM@0"9;D,#<'\4<P((O%!'N!=,2_*8
M=2G#\98VXFP5]&3DGN+H7J0`PDEH1=IT0:A:\9R9>`82%&A&G4=:H?EW)]8O
M\,XSAB*377B46K4V0ZHDH=O8,>2"RRC2)L;Y@V4075J\@\'VUW:`]J(B4P]!
MZ;W$61M;UV,RS-TC';0[4!R!44)Y@-4ZD`D*A3PWF49(CHSJT(?#QTJW]_R<
M<RD2VCIA4)0S-0IF$X[?N0L+<"AL5L$BJ(HRT80FX)D`I#B&PB;4T?A+*XD$
M-O$D)!4*>O7KUZ^-:AF7?ZX;([R:K]%5&XY9A;S^=<70_P!0X54?VMJW0!1P
M90`.9D_%0-A,.X&2)Z?RZU'),9$SCLKY&^:,%/"O599!]S=",.5N[\=9UR1[
M83@N0I0.<O0=S"(=PB8P@&X[&-OL80ZF```>@!KAC4:A:UH(Z>4>_LJ9H76S
M;5Q=Z+7;@%*KUZJJ+V*@[!7<L<B3J4H`.Q@_/4_M`("/4_0=C"&X;;;ZLEC;
M-/\`$2+ZNU%!(T]@0>_K65[W2ZR:DD'Z`E$XUNF/0NQ1V$Q`.IL82@``8VYM
MSG^4.H[COK#+:PS-:V3>0PJ/,X(?:"M8]K=Q<0%/70)IX=*BBP;"._:??O%0
M!!98-C&``$0_6=`$`]/3UZ=1U6.UABCDB9NV2/W.5SCKH="22!IT"#PJ_=YQ
M(C=XZ%!^2H16"!`,0A#@01-L0RJIDR@8#=P$*)A`I3=PB(?:.^JRV\<PVN+P
M%7RN<W4_ZI%)7>M()I0UTH[=H_)45-DD0.T0$2AOVD[S@0H"(B)2D`P%`NX]
M`VV#X:R-C8U_J`?K-FU3J=JKJO77M.OC5LB2L].0`L/@.RNGT*!C;"0_:`CL
M`*K%*4-MMB@!P`H=/0/CJYS6N))`W%FQ0`#M[E&H^E:S,GD8T,;M#0$^RW\E
M#QS<Q0(!/D#NW(<QU"&[OTBG,8!Z]?RZM;&UC&QM+@UI4:E?I53[S6#:T-:P
M`;6NW`>/?]=<)QR)-M@'8-M_G4W'MV[1$>[J8-O7UUADM(99Q<R%YE;T\[D_
MV5V_568RNWF1&AYZG:/R5&4:IGWVW#NZ&^<X?``#80-N78`^&LSV-?()7+ZC
M00"J:'7LZ^^O,(F`O*?;*E==>G;T]U031K8R8)_K2[#W`8JZP&WZ#V]_?W^W
MW!OV[[;]=M8Q;1M+G-WASNJ.=]6NGNJA@C,9C1&GN*'JNAZBNJL:BL.Z@=P_
M)ML=0FPD/[A3`)#%'N`X;[_'8-]7^FWT#;^;TR$53N_VEW#Z:NF9Z[0V0NVC
ML#G#Z4(7WUU/'-SB`G*J8Y=@*I[RWN!L`@/:H!^\H'`>NP]>GV:\[["WDM6V
M;]Y@8[</.]5':7+N/O)K+$[T9C<1AHE<T-)V@J`B:$)V"O01HEW&.('`P[=?
M<5#T$3;@'=L`@(CU#KL.O6X;FAI)0)T)'3^FO?VU;IIH-'*-!UK@&#4!`0(<
M!`!+O[JNXE';<#")]S!T^.J@#5=0[J#J/H*B@07#KH`>NX(2@Z!.SIV5R=FB
M(%`2&,!=M@,8Y@#M``#8!$0#8O3\@ZP7-M;W;F/G8"Z-VYO8A]WX*J2';E`1
MXUT&M0S,"'*!1,<I0[>T"J*$[>TX*``"4P"&XAL;](O0=PZ:SL6-[GM)W/ZJ
M5'N!T'NZ59''''`+=C0(AV)^/K7`QZ(`8O:8`4$YC`D=1/YC@`'-N0Q1*8?M
M#8=>5EE!&XN9OW$K]MQ_":RE[G-V%-J=PJWKE;@1ER1XZ9HP(I.O:J7+N.+)
M10LS-([]>`<3+/VVLLG'F4(1V+!TDF<4=R@H4#%_M#J1<6R;.-\CM\^`Y[H9
M0]PW..X#1`I*:'L2M%R;'.S6!GQ+0SSLVM5H('F!U":].U:UF(OPD>3:W82I
M'"'+/+_#++A?1+@E/`UIT;>WMSF*^G,JS"T&Q@YEHTC8Y-@=XZ/'M7+L[9DZ
M/[@G5*4B>NUY'YI\29=2<CQ^.DCY'(S:Z4/>TD(.QKT_-`)`70=U<@L.$<NE
MC;@[^=CL!&\N;'L8B@Z:AF[52@<>^ML*EU.+J=3K=0BDUT8>KUR!K,2@)S)@
MA&U^-;Q4>4B:)4$4C`T;%W!,A";]`#8`U\^SO%W<37CB\NN7N>[<YSM7DD_:
M)(Z^VNZ0Q>C916)#0R)@:$`'V0!V`=U36$>V.`@<JG:`B(%]U4H=QOSC!VG+
M\P@&V_V"/VZQQQLBVH-VT$#=YD!U/VEJ_:U"`$W$$IIJ/$5`&+;HE.9`IB`4
MIA23(J<"E$0'8B93&]L@&,/IMV@/701QAY>&M!<W:0``"/8-/>BU?<N?=.9)
M*5DC*M[-434#1VFGF6K69WB72+9RXQSR^G)JR.+KBC$]WQ'2*N)V)JE#,<@3
M+62L=H0(X:*2*%L<-X])B=5!8I?I@[`#L.8!VMOE;RUPC^.P%C<0^0/<STV*
M7`(/.6[P$_-#D/:*TL^%LKG*1YF=F[(Q:,<I`;_V5V]I[*NK*R2-[1Q3434(
M&P?K5`$#;=G<?L.!%#``=!'?;X:T[+>*-@9&"U@*H"1J??T\.E;IY,K`V1"-
MV[H/M=_U].E1",$``0.43_F]1.IW"!1$Q0,;NW,!#"(@`]`$=9)&^INWDH[K
MJ1^#I[JO,CG/+R&[G!#H.GT5T_"V8&`Y$S%.4!`@@JKL0!$#"4I>_8I>\-]@
MZ;B(_'6!]I"]K&.W;6$D>9PU/>5U]]6!!"VW`;Z+"H"#KKKT\:Y!@B3;Y/CO
M\IE`^(C\VQ@[]^[X[ZS".-L9B#6[2".@77_2^TOBJU;"UMN'-A``<==`?PU'
M*U1*!NTFW<02F*`FV$!V]2[[;]/Z1^T=8Q;1MC,:OVEFW5SB41-'$J#X@KVK
M5Q*MVH-JKT`\:UCO,WD,U2Y1TB.!;VA6P=`2`E`2`(@>\WYH`["(#ONE_-KZ
M3^3N/-YA[F4(C9DU7]%G=[:Y;R^<V]V'.=V=.WM]U8D29Q437:K`Z[_IG*;C
MVS@F*9Q2^9,%`[OUJ8*`&Z9OD,'KKK_W1_J_74-^\QW.^D?EJ:6^:[AE:YL6
M[V6;R-GL3Z.BD'TK(IMH6.:L^Q%H*AG1P:URM046B)E$VA$B-VK<1_6G$1UJ
M)\/;VK'-Q+/3E<I<7#JX]2$7J>E8Y<G(Y[71$@#JO]553S'RG8Y$D*)B;%ZZ
M_P"ZC&BC.DXY9*>ZS<6F9>NF\;,9-GFP?K'$M?)*3.Y*D<!.V061(```F`(]
M;<;?B\7=96_1]Q*]7;5):-NC5(`VLU`3M4]36^ASC;@-B:'!P"=FI[]#VU=Y
MD+EA%E\B>$ZU%2P$J.#,@XNP1%)IKJF:]E?E(>LW=\D8/^$[`F)9PDH(B`&3
M:DVW$`#43/%9HN%7ER\-^(N@'C0C;N>'(5`Z-TK<6.89!DXVR;BT`C3_`%3W
MGOKB5YFL<6>3[(]@L,Q[5">Y?F\2WI-38\>XITB+&CN'#GVS;?\`(9%DDZ*)
MA`")%4,.P%'7HN^+39+Y=V,EH&QW-JP/.X%244`(#JO?7G9F/2S)F>IBW$$:
M=.AJWZJ<DT>.V8LV84R2X=.<+V"X7'$>5X)%/\34CVC";D8^KY#@&PF[R3%)
M2!*0+[.X.V_>7<W<3MV]S@3E[.US-@C,NV-CV/7RD%H\AZJ'`[2HTZ]E>*TS
M8LY9V3!S@^1R(F@))'7M'A5"%LWW+">0)EE"V@A9RMOWD>G.1ZJ,E7+9&NBJ
M#]:8BX'C[+2+S`N4%3,CD%NHS6(/J/;J7MPUCDL=&)82V^+092X!#)U!":@M
M[T!!Z5J/O1T4DA<IW.4)V#N-2*[SBB=VX79HI12+I=5=-DV>K.V[<BQQ5!NC
M]8<3I((]W:0H"/:4`#6ZQ^!AMH3ZC09$T(_KKROR!<5:H)/:E76<$,N'FN9/
M'.)%R)PD,BMFP$[B?G'B)<P&'8PB)=DQ#[=Q#4'^8>%?:\2N;EQ;L(=H%7\"
M5(./7?IY6*V>X/>]P0CL]M;ER)1(4A1]2EV'^0-?(X((4=*[,T$-`/5*].JU
M6FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*A&(([[;==_41_JT4
MC4=:H2X!6)NJ&*)MNG9O]YCZ-?+N\^W;X5:Y]SM\A;N]G]51"D,';OMTVWVW
M^'V=-5/73I5S=R#?]KM]M1=4JM<#Z:4%<;&^W^D=545<HKMJE6TTI32E-*4T
MI6DS_$:9.:4_G#CJ*5>HH+J\9:8\]LZZ)#E17R9EI(3"F8>X"'49@`&VV$2B
M`#ZZ^POY>+2&XXW>AY'J?$Z!0I&V/H.IKY<^<O(;C$\@A9&'&$LU0%.WMK`-
M^_E@3\Z01-O]CA'I_,.N_?<\?Z)KD?\`',OZ+OH-=BY^8$*<I)`I/<*8IQ(Y
M3*82G`2G+WE,!@*<IA`0`=A*(@/0=><\?B))V]:I_',_Z+OH/Y*F>F<H6=1N
ME3N)%6[]S5+##V..9JKMP07DZ^^3F(EHOW#[8,E))N0QRF`4^GS`("("N>.0
MSXYUL1]J0:>ZKX>?7,<X(#MJ*=#7CA.2HQ=N@[<[G%G;UC:XJT2+I5Z19PZ<
MM+`A//US',8PF</'"9S&-ZG,("._35<KP^T?8,L`!L>P@IV:'N^JMA'\Q9QD
M(W%=H77LZ'MJ8<R<J([(F5LHWMN_!-I><A7FU$2,Y1#="T3TC*=IR;@'5"0$
MGIL!1$H;!TUAQW$K?[@DL'!`UNT`Z$H$K"_YAW+KPN`<B]4_'7@OG*H<@6M:
MX2KX#S,I%U]G/N%G*"II"2KU<BH1S+N!$>Q=S8RQY55QV_.$P?VC;Y;7B=I!
M;1PL:T-:P!/=]7AW=E7.Y_*7$ZZU*BG(!JL8AG$JHY,BW;LT3NGP+F09-">T
MT9("JH;VF;1/Y4DR[$3+T``#5S\!%"\!@Z]U>:;GDKB"`[Z/R5#-G9B(`<TB
M@4`V$-W+<-@^'J(!\?CK918B$#SH!XZ5A/-YI?U8W`D]QJ_/Q:YC93GD8X?P
MQ7Z*II++C)N0I5T#".T!85SCVE^8=BI>OPURKYR63(>#W.S5VQW37L-3?Y:\
MBER',8(9W)'N&IT'7QTK]&5$1,'>(#UV$-PVZ"&_IT^W7P.T$``]4K[***4U
M"U'U6J4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*59SG'_``3?MJP'DE_A4"\_A"7X07-X8C&TC6_K'WT@
ML#9#$)4L`+_ZOL!$!;_5>]VCW^YJ1X;^+/AS]RB]7_\`6,JK_P#+"+[>SP2H
MAF_X3^.;][_">KJOQ'I>GT[=Y5.Y--WBM4HW\4_Z/CL_O<:?]S6V_P`T?[Q?
MM-:W_+?^[?[/3?Q3_H^.S^]QI_W-/\T?[Q?M-/\`+?\`NW^STW\4_P"CX[/[
MW&G_`'-5_P`TNS^(OVFG^6_]V_V>HG_Y4[!L'COWV#;8>-?W>GR[>F@_Q07_
M`-PK_P"IJH_PZ[/X<3_T]0S?Y573N#QX?=N/&?\`]P:K_FC_`'A_:?R5>/\`
M#KL_AS_Z%10_RJ=@Z>._T_2XU_U%V]=4_P`TO[Q?M-8C_ANO_MO]GKJ;_*HZ
M;AX[OY3<:OZRCI_FE_>+]IH/\-_[M_L]<&_RJ.P>GCO]`_-'C0(_#],H$VVU
M@N/\5/1.W^(5TZ_$=_CI6:#_``U]4>I_#NS7I\.O2IGHG^7!^VE<_=2'"3]X
M_P!?_P#4!QX;C^-Z_%_:4[?V9"O%"=_$O8[]OI![_;[M^FO!E1S[[N/WJ<YZ
M&T[MXD1.U=YVHE>K%G@'QG_\@8,R;OS#$'?[@)J^]#M]A+LW[?;)MOOOMVA]
MO748C7TVJJH.O7W^/?4S*+HB>'3W>'=475]4II2FE*:4II2FE*:4II2FE*:4
GII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
